For example, a recent small trial of tofacitinib in SSc did show evidence of inhibiting the interferon-regulated genes expressed by the CCL19+ fibroblasts, which suggests it is the resident fibroblasts that are being targeted (5). This evidence concerns the gene CCL19 and systemic sclerosis.